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Abstract: A low serum level of vitamin D has been associated with an increased incidence of gastrointestinal tract cancers. 
However, the effects of vitamin D3 have not been investigated in gastric cancer and cholangiocarcinoma. In the present study, 
we found that vitamin D3 treatment significantly suppressed the viability of gastric cancer and cholangiocarcinoma cells. 
Moreover, vitamin D3 had a synergistic effect with other anti-cancer drugs, such as paclitaxel, adriamycin, and vinblastine, for 
suppressing cell viability. To determine the underlying mechanism involved in the regulation of viability by vitamin D3, we 
examined the effects of vitamin D3 on expression of hedgehog signaling target genes, which has been associated with gastric 
cancer and cholangiocarcinoma. Vitamin D3 treatment decreased the level of mRNA expression of patched1, Gli1, cyclin D1, 
and Bcl2, suggesting the possibility that vitamin D3 may act through regulation of hedgehog signaling. From the above results, 
we conclude that vitamin D3 regulates cell viability in gastric cancer and cholangiocarcinoma.  
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risk for colorectal [6], breast [7], and prostate cancers [8]. 
Moreover, Giovannucci et al. [9] studied the relationship 
among dietary and supplementary vitamin D, physical 
activity, body mass index, and sunlight exposure in 47,800 
individuals and found a strong association between low levels 
of vitamin D3 and increased cancer incidence, particularly for 
cancers of the digestive system. The second class of evidence 
is derived from altered expression of vitamin D3-related 
genes in many tumor types. Overexpression of CYP24, which 
downregulates the level of the active form of vitamin D3, has 
been reported in various cancers, including colon [10, 11] 
and esophageal [12] cancers. Amplification of 20q13.2, which 
harbors the CYP24 gene, has been reported in gastric and 
breast cancers [13, 14]. The third class of evidence is derived 
from studies about vitamin D3-related gene knockout mice. 
In vitamin D receptor knockout mice, a higher incidence 
of lymphoblastic and thymic lymphoma and mammary 
hyperplasia is observed [15]. 
Introduction
Vitamin D3 (1, 25-dihydroxyvitamin D3) has been 
associated with the regulation of Ca
2+ and Pi transport 
and bone mineralization [1, 2]. This association has been 
supported by vitamin D3-related gene knockout studies [3-
5]. However, recent studies indicate that vitamin D3 affects 
cell proliferation, differentiation, and gene regulation [2]. 
Moreover, three kinds of evidence suggest an association 
between vitamin D3 and carcinogenesis. The first class of 
evidence is derived from epidemiological studies. A low 
serum vitamin D3 level has been associated with an increased Vitamin D3 in gastric cancer and cholangiocarcinoma
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Gastric cancer is the second leading cause of cancer-re-
lated deaths in the world [16]. Gastric cancer is a malignant 
tumor that originates from gastric mucosa and is classified 
into intestinal and diffuse types. Many factors are related to 
the cause of gastric cancer, such as a high-salt diet, ingestion 
of grilled meats and fish, and infection by Helicobacter 
pylori [17]. These bacterial, environmental, and host factors 
contribute to the molecular changes of gastric cancer. Despite 
advances in diagnostic technology such as endoscopy, the 
cure rate for gastric cancer is still poor due to fast growth 
and metastasis. Cholangiocarcinoma is a malignant tu  mor 
that originates from bile duct epithelial cells [18]. Intra-
hepatic cholangiocarcinoma is the second most common 
sub  type of primary hepatobilliary cancer [18, 19]. Chronic 
inflammation of the liver contributes to the malignant 
transformation of cholangiocytes. The main reasons for the 
poor prognosis of patients with cholangiocarcinoma are due 
to diagnostic difficulty, extensive local tumor invasion, and 
multidrug resistance. Many molecular factors contribute to 
carcinogenesis of gastric cancer and cholangiocarcinoma [20-
23]. Interestingly, hedgehog (Hh) signaling contributes to the 
progression of both cancers [24]. 
Although vitamin D3 regulates the growth of various 
cancers, vitamin D3 has not been examined in gastric cancer 
and cholangiocarcinoma. Herein, we report that vitamin D3 




SNU1, SNU638, and SNU1079 cells were cultured with 
RPMI-1640, 25 mM HEPES, 10% fetal bovine serum (FBS), 
and 1× penicillin/streptomycin. HuCCT1 cells were cultured 
in RPMI-1640, 10% FBS, and 1× penicillin/streptomycin at 
37
oC in a 5% CO2 incubator. SNU1, SNU638, and SNU1079 
cells were purchased from the Korea Cell Line Bank (Seoul, 
Korea). HuCCT1 cells were purchased from the Health 
Science Research Resources Bank (Osaka, Japan). Vitamin 
D3, cyclopamine, paclitaxel, adriamycin, and vinblastine were 
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Cell viability assay
Cells were seeded at a density of 1×10
3 (SNU1 and 
SNU638), 1.5×10
3 (HuCCT1), or 4×10
3 cells (SNU1079) 
per well in 96-well plates and treated with the indicated 
concentrations of vitamin D3. Four days following treatment, 
10 μl of Ez-Cytox reagent (ITSBio, Seoul, Korea) was added 
to the wells, and the cells were incubated for an additional 2 
hours under normal cell culture conditions. Cell viability was 
measured by absorbance at 450 nm using an ELISA reader 
(Tecan, Mannedorf, Switzerland). 
Real-time polymerase chain reaction (PCR)
Total RNA was extracted using a RNeasy Mini kit (Qia-
gen, Valencia, CA, USA) and processed based on the manu-
facturer’s manual. cDNA was synthesized with MMLV 
reverse transcriptase (Promega, Madison, WI, USA), dNTP, 
and oligo-dT primers. Real-time PCR was conducted using 
FastStart Universal SYBR Green Master Mix (Roche Applied 
Science, Indianapolis, IN, USA) in an ABI Prism 7500 
sequence detector (Applied Biosystems, Foster City, CA, 
USA). The primer sequences were as follows: Ptch1 (F: 5'-
AAC CCC TGG ACG GCC GGG AT-3', R: 5'-AGG ATG 
ACC ACG GGC ACG GCA-3'); Gli1 (F: 5'-TGC TGG ATG 
GGC GGG AGG ACC-3', R: 5'-CCC CGT GGA TGT GCT 
CGC TGT-3'); CCND1 (F: 5'-CGC GCA GAC CTT CGT 
TGC CCT-3', R: 5'-GCC TTG CAC TGC GGC CAC CA-3'); 
Bcl2 (F: 5'-CTG GGG GAG GAT TGT GGC CTT CTT TG-
3', R: 5'-TCC AGG TGT GCA GGT GCC GGT TC-3'); and 
β-actin (F: 5'-GCG AGC ACA GAG CCT CGC CT-3', R: 5'-
GCC TTG CAC ATG CCG GAG CC-3'). 
Data analysis
All data are presented as mean±SD. All experiments were 
repeated at least four times. The difference between the mean 
values of the two groups was evaluated using the Student’s 
t-test (unpaired comparison). We used a one-way analysis of 
variance, followed by Tukey’s multiple comparison to compare 
more than three groups. A P-value<0.05 was considered 
statistically significant.
Results
Vitamin D3 inhibits viability of gastric cancer and 
cholangiocarcinoma cells
We used SNU1 and SNU638 cells to test the effect of 
vitamin D3 on the viability of gastric cancer cells. Cells 
were seeded in 96-well plates and treated with different 
concentrations of vitamin D3 in the presence of 1% FBS. After Anat Cell Biol 2011;44:204-209 Sungmin Baek, et al 206
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4 days, we measured the absorbance. Vitamin D3 treatment 
significantly inhibited the viability of gastric cancer cells 
compared to that in control cells in a dose-dependent manner 
(Fig. 1A, B). Specifically, treatment with 10 μM vitamin D3 
suppressed viability by >80%. Subsequently, we tested the 
effect in HuCCT1 and SNU1079 (cholangiocarcinoma) 
cells. Vitamin D3 treatment inhibited viability of cholangio-
carcinoma cells as in gastric cancer cells (Fig. 1C, D). 
Vitamin D3 shows a synergistic effect with other anti-
cancer drugs
Brüggemann et al. [25] reported that vitamin D3 does 
not exert a synergistic effect with other anti-cancer drugs. 
However, it remains unclear whether or not vitamin D3 has 
a synergistic effect with other anti-cancer drugs in gastric 
cancer and cholangiocarcinoma cells. Thus, we seeded SNU1 
and HuCCT1 cells in 96-well plates and added vitamin D3 
with anti-cancer drugs, such as paclitaxel, adriamycin, and 
vinblastine in the presence of 10% FBS. Cell viability was 
measured after 2 days of treatment. As shown in Fig. 2, a 
Fig. 1. Effect of vitamin D3 on gastric cancer cell and cholangiocarcinoma cell viability. SNU1 (A), SNU638 (B), HuCCT1 (C), and SNU1079 
(D) cells were treated with the indicated concentrations of vitamin D3 in 96­well plates in the presence of 1% fetal bovine serum. The cells were 
further incubated for 4 days, and the viability assay was performed. Ethanol (vehicle) or cyclopamine (10 mM) were used as negative and positive 
controls, respectively.  Data are expressed as percent change (mean±SD) compared to the control (*P<0.01, ANOVA followed by Tukey’s multiple 
comparison).Vitamin D3 in gastric cancer and cholangiocarcinoma
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significant difference was observed in cell viability between 
the vitamin D3 alone and the combined with anti-cancer 
drugs groups. Treatment with vitamin D3 alone decreased the 
average survival rate of SNU1 and HuCCT1 cells by 57% and 
41% respectively (Fig. 2). However, combined treatment with 
other drugs decreased the survival rate by >70%. This result 
indicates that vitamin D3 can function synergistically with 
other anti-cancer drugs.
Vitamin D3 inhibits the expression of Hh signaling 
target genes 
To investigate the underlying mechanism involved in 
the regulation of viability by vitamin D3, we examined Hh 
signaling because cyclopamine, a specific inhibitor of the Hh 
signaling pathway, almost completely suppressed cancer cell 
viability (Fig. 1). Furthermore, Bijlsma et al. [26] reported 
that vitamin D3 is an antagonist of Hh signaling. However, 
the relationship between vitamin D3 and Hh signaling is not 
well-studied in cancer cells. To determine whether or not 
vitamin D3 is associated with Hh signaling in cancer cells, 
Fig. 2. Synergistic effect of vitamin D3 with anti­cancer drugs. SNU1 (A) and HuCCT1 (B) cells were treated with paclitaxel (0.5 nM), adriamycin 
(ADR, 150 nM), or vinblastine (100 nM) with or without vitamin D3 (35 mM) in the presence of 10% fetal bovine serum. The cell viability 
assay was performed 2 days after treatment. Ethanol (vehicle) was used as the negative control. Data are expressed as percent change (mean±SD) 
compared to the control (*P<0.01, compared to the single treatment, Student’s t-test).
Fig. 3. Vitamin D3 regulates the expression of Hh signaling target genes. SNU1 (A) and HuCCT1 (B) cells were seeded at 1×10
5/well in 
6-well plates. After 1 day, the cells were treated with 10 μM vitamin D3. One day later, RNA was purified from the cells, and real-time 
PCR was performed. Ethanol (vehicle) was used as the negative control. Data are expressed as percent change (mean±SD) compared to 
control  (
*P<0.01, 
†P<0.05, Student’s t-test).Anat Cell Biol 2011;44:204-209 Sungmin Baek, et al 208
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we assessed Hh signaling activity by measuring the Ptch1 
and Gli1 expression levels, which are direct target genes of 
Hh signaling. SNU1 and HuCCT1 cells were treated with 10 
μM vitamin D3 one day after cell seeding. One day following 
the treatment, the Ptch1 and Gli1 mRNA expression level 
decreased sharply (Fig. 3). We also examined effects on the 
expression of other Hh signaling targets, including cyclin 
D1 and bcl2. In particular, we have shown previously that 
inhibiting Hh signaling reduces bcl2 expression in gastric 
cancer cells [27]. Vitamin D3 treatment reduced cyclin D1 
and bcl2 expression (Fig. 3). These results suggest that vitamin 
D3 may act as an antagonist of Hh signaling in gastric cancer 
and cholangiocarcinoma cells.
Discussion
Vitamin D3 has been widely used clinically, and the proper 
dosage and side effects have been well-documented [28]. In 
the present study, we showed, for the first time, that gastric 
cancer and cholangiocarcinoma cells are sensitive to vitamin 
D3, and that vitamin D3 has synergism with other cancer 
drugs. Moreover, we also showed that the actions of vitamin 
D3 are possibly mediated through inhibition of Hh signaling. 
The expression of Hh signaling target genes was regulated 
by vitamin D in the present study (Fig. 3). Hh signaling is 
one of the most important signaling pathways regulating pro-
liferation, differentiation, embryogenesis, and cancer [29]. In 
mammals, Hh consists of three different members, including 
Sonic hedgehog, Indian hedgehog, and Desert hedgehog 
[30]. The trigger for signaling is the Hh ligand binding to 
a 12-pass transmembrane protein patched (Ptch1), which 
resembles the Niemann-Pick disease type C1 (NPC1) protein. 
The NPC1 protein is involved in cholesterol trafficking and 
has a pump function [26]. After Hh binds to Ptch1, Ptch1 no 
longer blocks the 7-pass transmembrane protein, smoothened 
(Smo), and subsequently the intracellular signaling cascade 
is activated, including Fused, protein kinase A, GSK3, CKI, 
and Gli. Finally, the Gli protein is activated and translocated 
to the nucleus where it turns on target genes. However, in 
the absence of Hh, Smo is continuously repressed by Ptch1. 
Finally, the Hh target genes are turned off.
The association between vitamin D and Hh signaling was 
first reported by Bijlsma et al. [26]. Bijlsma et al. [26] reported 
that Ptch1 can secrete 3β-hydroxysteroids, which inhibit 
Smo on other cells. Vitamin D3 directly binds to Smo with 
high affinity in a cyclopamine-sensitive manner. Moreover, 
Bijlsma et al. [26] showed that treating zebrafish embryos 
with vitamin D3 mimics the Smo
-/- phenotype. Their report 
suggested that vitamin D3 can be used as an anti-cancer drug. 
In contrast, Brüggemann et al. [25] reported that vitamin D3 
inhibits pancreatic cancer cell viability in the presence of 0.5% 
serum; however, it does not inhibit the pancreatic cancer cell 
viability in the presence of 10% serum. Moreover, vitamin 
D3 did not show any synergism with other anti-cancer drugs 
for inhibiting cell viability. Brüggemann et al. [25] suggested 
that vitamin D3 is not an efficient anti-cancer drug. However, 
in the present study, vitamin D3 had the ability to inhibit 
cell viability and showed a synergistic effect with other anti-
cancer drugs in 10% serum, as shown in Fig. 2. Hence, our 
data indicate that vitamin D3 could be used as an anti-cancer 
drug, and its effect may depend on cell type.
Vitamin D3 is related to cancer via various signaling 
pathways [2]. However, in the present study, we focused on 
Hh signaling because cyclopamine, a specific inhibitor of Hh 
signaling, almost completely suppressed cancer cell viability, 
which was consistent with previous reports [24]. Although 
it is unclear how the Hh signaling pathway is activated in 
gastric cancer and cholangiocarcinoma, it is clear that Hh 
signaling activity is critical for viability [24, 27]. We showed 
that vitamin D3 reduced the expression of Hh signaling target 
genes (Fig. 3), suggesting the possibility that Hh signaling 
may play a critical role in vitamin D3-induced inhibition 
of viability. Future studies such as Gli1 overexpression are 
required to confirm this possibility. 
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